Pharma Mergers May Have Tougher Time Clearing FTC Under New Review Scheme
Executive Summary
FTC is working with Canadian and European enforcement agencies to come up with new approach to merger reviews that could look at effects on innovation and companies' past conduct. FTC to review closed mergers to see if corrective action is necessary, FTC acting chair says.
You may also be interested in...
More Pharma Mergers Will Be Presumed Anticompetitive Under New FTC/DOJ Guidelines
The FTC and DOJ revised draft merger guidelines could make it more difficult for companies to clear M&A reviews, but the agencies may have trouble winning challenges in court.
FTC Targets Amgen Bundling And Rebates In Suit To Block Horizon Acquisition
Complaint marks first time agency has raised novel theories of competitive harm in pharma merger and is rare instance in which it has filed a complaint without a consent decree. Last time FTC has gone to court to block a pharma merger was in 2008.
Pfizer/Seagen Merger Seems Set To Clear As US FTC Sticks To Traditional Review
Pink Sheet infographic breaks down the big pharma deals and required divestitures over the past four years. Seagen reports that Pfizer's acquisition of the company is expected to close late this year or in early 2024.